Search Results for: DYNLL1

112 interactions involving DYNLL1 - dynein light chain LC8-type 1 found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
PARD3 par-3 family cell polarity regulator
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • Tight junction interactions
PAX6 paired box 6
  • Regulation of gene expression in beta cells
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Aniridia
  • Polymicrogyria; Bilateral frontal polymicrogyria (BFP); Bilateral frontoparietal polymicrogyria (BFPP); Bilateral perisylvian polymicrogyria (BPP); Bilateral parasagittal parieto-occipital polymicrogyria (BPOP); Bilateral generalised polymicrogyria (BGP); Unilateral Polymicrogyria (ULP)
  • Ocular coloboma, including: Coloboma of iris choroid and retina (COI); Coloboma of optic nerve (COLON)
PCM1 pericentriolar material 1
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
PFKM phosphofructokinase, muscle
  • Glycolysis
  • Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
PFKP phosphofructokinase, platelet
  • Glycolysis
PKIA cAMP-dependent protein kinase inhibitor alpha
  • 3,5-Diiodotyrosine
  • Hydroxyfasudil
  • (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine
  • (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE
  • (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
  • (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE
  • N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE
  • 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE
  • (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
  • (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • H-89
  • 5-(2-methylpiperazine-1-sulfonyl)isoquinoline
  • N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE
  • 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • 3-pyridin-4-yl-1H-indazole
  • 5-benzyl-1,3-thiazol-2-amine
  • 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine
  • 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium
  • Fasudil
  • Myristic acid
  • A-674563
  • 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE
  • Y-27632
PKIB cAMP-dependent protein kinase inhibitor beta
PKIG cAMP-dependent protein kinase inhibitor gamma
POLH DNA polymerase eta
  • Translesion Synthesis by POLH
  • Termination of translesion DNA synthesis
  • HDR through Homologous Recombination (HRR)
  • Disorders of nucleotide excision repair, including: Xeroderma pigmentosum (XP); Cockayne syndrome (CS); UV-sensitive syndrome (UVS); Trichothiodystrophy (TTD); Cerebro-oculo-facio-skeletal syndrome (COFS); XFE progeroid syndrome
PPP3R2 protein phosphatase 3 regulatory subunit B, beta
  • Cyclosporine
  • Voclosporin
RAB4A RAB4A, member RAS oncogene family
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Synthesis of PIPs at the plasma membrane
  • TBC/RABGAPs
  • RAB geranylgeranylation
  • MET receptor recycling
RACK1 receptor for activated C kinase 1
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • TNFR1-mediated ceramide production
  • Copper
RASGRP4 RAS guanyl releasing protein 4
  • FCERI mediated NF-kB activation
  • RAF/MAP kinase cascade
RGS2 regulator of G protein signaling 2
  • G alpha (q) signalling events
SHROOM3 shroom family member 3
SLC13A1 solute carrier family 13 member 1
  • Sodium-coupled sulphate, di- and tri-carboxylate transporters
SMCP sperm mitochondria associated cysteine rich protein
TERT telomerase reverse transcriptase
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Zidovudine
  • Grn163l
  • Tertomotide
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
THAP10 THAP domain containing 10
THAP8 THAP domain containing 8

Page 5 out of 6 pages